## Erik L. Grove

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3097290/publications.pdf

Version: 2024-02-01

207 papers 7,710 citations

76326 40 h-index 82 g-index

218 all docs

218 docs citations

218 times ranked

9765 citing authors

#	Article	IF	CITATIONS
1	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39, 213-260.	2.2	2,246
2	Transcatheter Aortic Valve Thrombosis. Journal of the American College of Cardiology, 2016, 68, 2059-2069.	2.8	312
3	Initial assessment and treatment with the Airway, Breathing, Circulation, Disability, Exposure (ABCDE) approach. International Journal of General Medicine, 2012, 5, 117.	1.8	176
4	Immature platelets in patients with acute coronary syndromes. Thrombosis and Haemostasis, 2009, 101, 151-153.	3.4	171
5	Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ: British Medical Journal, 2011, 342, d2690-d2690.	2.3	161
6	Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. European Heart Journal, 2013, 34, 1708-1713.	2.2	159
7	Reduction in radiation exposure in cardiovascular computed tomography imaging: results from the PROspective multicenter registry on radiaTion dose Estimates of cardiac CT anglOgraphy iN daily practice in 2017 (PROTECTION VI). European Heart Journal, 2018, 39, 3715-3723.	2.2	149
8	Coronary CT Angiographic and Flow Reserve-Guided Management of Patients With Stable Ischemic Heart Disease. Journal of the American College of Cardiology, 2018, 72, 2123-2134.	2.8	138
9	Clinical Use of Coronary CTA–Derived FFRÂfor Decision-Making in Stable CAD. JACC: Cardiovascular Imaging, 2017, 10, 541-550.	5.3	126
10	A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thrombosis and Haemostasis, 2010, 103, 1245-1253.	3.4	125
11	Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. Journal of Thrombosis and Haemostasis, 2011, 9, 185-191.	3.8	123
12	The causal role of megakaryocyte–platelet hyperactivity in acute coronary syndromes. Nature Reviews Cardiology, 2012, 9, 658-670.	13.7	121
13	The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart, 2010, 96, 368-371.	2.9	111
14	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. European Heart Journal, 2018, 39, 1672-1686f.	2.2	106
15	Platelet aggregation is dependent on platelet count in patients with coronary artery disease. Thrombosis Research, 2012, 129, 56-61.	1.7	100
16	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal, 2017, 38, ehw454.	2.2	86
17	Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. European Heart Journal, 2021, 42, 2265-2269.	2.2	81
18	Aspirin response evaluated by the VerifyNowâ,,¢ Aspirin System and Light Transmission Aggregometry. Thrombosis Research, 2008, 123, 267-273.	1.7	78

#	Article	IF	Citations
19	New Oral Anticoagulants. Drugs, 2012, 72, 1739-1753.	10.9	76
20	Timing of Acute Myocardial Infarction in Patients Undergoing Total Hip or Knee Replacement. Archives of Internal Medicine, 2012, 172, 1229.	3.8	67
21	Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporosis International, 2014, 25, 757-762.	3.1	64
22	Patients With Previous Definite Stent Thrombosis Have a Reduced Antiplatelet Effect of Aspirin and a Larger Fraction of Immature Platelets. JACC: Cardiovascular Interventions, 2010, 3, 828-835.	2.9	62
23	Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thrombosis Research, 2010, 126, e318-e322.	1.7	61
24	Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance. Current Pharmaceutical Design, 2012, 18, 5344-5361.	1.9	59
25	Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure. Europace, 2020, 22, 1149-1161.	1.7	58
26	Contemporary use of glycoprotein IIb/IIIa inhibitors. Thrombosis and Haemostasis, 2012, 107, 215-224.	3.4	54
27	Platelet Turnover in Stable Coronary Artery Disease – Influence of Thrombopoietin and Low-Grade Inflammation. PLoS ONE, 2014, 9, e85566.	2.5	50
28	Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. Thrombosis and Haemostasis, 2015, 114, 459-468.	3.4	50
29	Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS). Stroke, 2018, 49, 2568-2576.	2.0	50
30	The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. Thrombosis and Haemostasis, 2014, 112, 1142-1150.	3.4	49
31	A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: Comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. Thrombosis Research, 2014, 134, 1253-1264.	1.7	48
32	Mouth-to-mouth ventilation is superior to mouth-to-pocket mask and bag-valve-mask ventilation during lifeguard CPR: A randomized study. Resuscitation, 2011, 82, 618-622.	3.0	47
33	Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies. Heart, 2016, 102, 1883-1889.	2.9	45
34	Use of Nonâ€Vitamin K Antagonist Oral Anticoagulants 2008–2016: A Danish Nationwide Cohort Study. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 452-463.	2.5	45
35	Computed tomography derived fractional flow reserve testing in stable patients with typical angina pectoris: influence on downstream rate of invasive coronary angiography. European Heart Journal Cardiovascular Imaging, 2018, 19, 405-414.	1.2	45
36	The platelet polymorphism PIA2 is a genetic risk factor for myocardial infarction. Journal of Internal Medicine, 2004, 255, 637-644.	6.0	43

#	Article	IF	CITATIONS
37	Rapid evaluation of platelet function using the Multiplate® Analyzer. Platelets, 2014, 25, 628-633.	2.3	43
38	24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. International Journal of Cardiology, 2014, 175, 274-279.	1.7	43
39	Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 221-234.	3.0	43
40	Immature platelets in patients with acute coronary syndromes. Thrombosis and Haemostasis, 2009, 101, 151-6.	3.4	43
41	Genetic Determinants of On-Aspirin Platelet Reactivity: Focus on the Influence of PEAR1. PLoS ONE, 2014, 9, e111816.	2.5	39
42	Evaluation of aspirin response by Multiplate $\hat{A}^{\text{@}}$ whole blood aggregometry and light transmission aggregometry. Platelets, 2009, 20, 415-420.	2.3	38
43	A changing landscape: Temporal trends in incidence and characteristics of patients hospitalized with venous thromboembolism 2006–2015. Thrombosis Research, 2019, 176, 46-53.	1.7	38
44	Pharmacogenetics of the Antiplatelet Effect of Aspirin. Current Pharmaceutical Design, 2012, 18, 5294-5308.	1.9	37
45	Determinants of Reduced Antiplatelet Effect of Aspirin in Patients with Stable Coronary Artery Disease. PLoS ONE, 2015, 10, e0126767.	2.5	37
46	Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. Thrombosis Research, 2009, 124, 96-100.	1.7	36
47	Platelet Function Testing in Atherothrombotic Disease. Current Pharmaceutical Design, 2012, 18, 5379-5391.	1.9	35
48	Treatment Changes among Users of Nonâ€Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 187-194.	2.5	35
49	von Willebrand Factor and Venous Thromboembolism: Pathogenic Link and Therapeutic Implications. Seminars in Thrombosis and Hemostasis, 2018, 44, 249-260.	2.7	35
50	TALOS: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Test the Effects of Citalopram in Patients with Acute Stroke. International Journal of Stroke, 2015, 10, 985-987.	5.9	34
51	Platelet characteristics in patients with essential thrombocytosis. Cytometry Part B - Clinical Cytometry, 2018, 94, 918-927.	1.5	33
52	Fibrin Clot Structure and Platelet Aggregation in Patients with Aspirin Treatment Failure. PLoS ONE, 2013, 8, e71150.	2.5	32
53	Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. Platelets, 2015, 26, 230-235.	2.3	31
54	Clopidogrel and the risk of osteoporotic fractures: a nationwide cohort study. Journal of Internal Medicine, 2012, 272, 385-393.	6.0	30

#	Article	IF	CITATIONS
55	Platelet function testing and prediction of procedural bleeding risk. Thrombosis and Haemostasis, 2013, 109, 817-824.	3.4	30
56	Antiplatelet therapy in acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2015, 16, 2133-2147.	1.8	30
57	Update on oral antiplatelet therapy: principles, problems and promises. Future Cardiology, 2009, 5, 247-258.	1.2	29
58	Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation. Europace, 2017, 19, euw241.	1.7	29
59	Application of Low Tube Potentials inÂCCTA. JACC: Cardiovascular Imaging, 2020, 13, 425-434.	5.3	29
60	Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists. Journal of Thrombosis and Haemostasis, 2013, 11, 1627-1639.	3.8	28
61	The influence of low-grade inflammation on platelets in patients with stable coronary artery disease. Thrombosis and Haemostasis, 2015, 114, 519-529.	3.4	28
62	Are we ready for a gender-specific approach in interventional cardiology?. International Journal of Cardiology, 2019, 286, 226-233.	1.7	28
63	Gastrointestinal Events with Clopidogrel: A Nationwide Population-Based Cohort Study. Journal of General Internal Medicine, 2013, 28, 216-222.	2.6	27
64	Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction. Platelets, 2013, 24, 528-537.	2.3	27
65	Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. Thrombosis and Haemostasis, 2013, 109, 920-929.	3.4	27
66	Platelet Function Tests: Preanalytical Variables, Clinical Utility, Advantages, and Disadvantages. Methods in Molecular Biology, 2017, 1646, 305-320.	0.9	27
67	Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation. Heart, 2019, 105, 742-748.	2.9	27
68	Antiplatelet Therapy in Patients with Diabetes Mellitus. Current Vascular Pharmacology, 2012, 10, 494-505.	1.7	27
69	New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications. Acta Anaesthesiologica Scandinavica, 2014, 58, 651-659.	1.6	25
70	Platelets and Antiplatelet Therapy in Patients with Coronary Artery Disease and Diabetes. Seminars in Thrombosis and Hemostasis, 2016, 42, 234-241.	2.7	25
71	Coronary artery disease-associated genetic variants and biomarkers of inflammation. PLoS ONE, 2017, 12, e0180365.	2.5	25
72	Increased platelet turnover in patients with previous definite stent thrombosis. Journal of Thrombosis and Haemostasis, 2011, 9, 1418-1419.	3.8	23

#	Article	IF	Citations
73	Myocardial Perfusion Imaging Versus Computed Tomography Angiography–Derived Fractional Flow Reserve Testing in Stable Patients With Intermediateâ€Range Coronary Lesions: Influence on Downstream Diagnostic Workflows and Invasive Angiography Findings. Journal of the American Heart Association, 2017, 6, .	3.7	23
74	Sex Differences in Treatment Quality of Self-Managed Oral Anticoagulant Therapy: 6,900 Patient-Years of Follow-Up. PLoS ONE, 2014, 9, e113627.	2.5	22
75	Primary Prevention of Cardiovascular Events with Aspirin: Toward More Harm than Benefit—A Systematic Review and Meta-Analysis. Seminars in Thrombosis and Hemostasis, 2019, 45, 478-489.	2.7	22
76	Gastrointestinal bleeding and the risk of colorectal cancer in anticoagulated patients with atrial fibrillation. European Heart Journal, 2022, 43, e38-e44.	2.2	22
77	Effect of long-term remote ischaemic conditioning on platelet function and fibrinolysis in patients with chronic ischaemic heart failure. Thrombosis Research, 2017, 153, 40-46.	1.7	21
78	Platelet microRNA expression and association with platelet maturity and function in patients with essential thrombocythemia. Platelets, 2020, 31, 365-372.	2.3	21
79	Influence of renal function and platelet turnover on the antiplatelet effect of aspirin. Thrombosis Research, 2012, 129, 434-440.	1.7	20
80	Heart failure in patients treated with bisphosphonates. Journal of Internal Medicine, 2013, 274, 342-350.	6.0	20
81	Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study. Pharmacoepidemiology and Drug Safety, 2018, 27, 174-181.	1.9	19
82	Realâ€world use of cardioprotective glucoseâ€lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019. Diabetes, Obesity and Metabolism, 2021, 23, 520-529.	4.4	19
83	Reduction of Myocardial Infarction and All-Cause Mortality Associated to Statins in Patients Without Obstructive CAD. JACC: Cardiovascular Imaging, 2021, 14, 2400-2410.	<b>5.</b> 3	19
84	Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction. Thrombosis and Haemostasis, 2012, 108, 140-147.	3.4	17
85	Topical Antimycotics for Oral Candidiasis in Warfarin Users. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 368-372.	2.5	17
86	Detection of biomarkers using a novel proximity extension assay in patients with ST-elevation myocardial infarction. Thrombosis Research, 2018, 172, 21-28.	1.7	17
87	Imbalance between Fibrin Clot Formation and Fibrinolysis Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease. Thrombosis and Haemostasis, 2020, 120, 075-082.	3.4	17
88	Calprotectin and Platelet Aggregation in Patients with Stable Coronary Artery Disease. PLoS ONE, 2015, 10, e0125992.	2.5	17
89	Generic switching of warfarin and risk of excessive anticoagulation: a Danish nationwide cohort study. Pharmacoepidemiology and Drug Safety, 2016, 25, 336-343.	1.9	16
90	A genetic risk score predicts cardiovascular events in patients with stable coronary artery disease. International Journal of Cardiology, 2017, 241, 411-416.	1.7	16

#	Article	IF	Citations
91	Fibrin clot lysis assay: Establishment of a reference interval. Thrombosis Research, 2018, 167, 9-11.	1.7	16
92	All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f93-f100.	3.0	16
93	Immature Platelets and Risk of Cardiovascular Events among Patients with Ischemic Heart Disease: A Systematic Review. Thrombosis and Haemostasis, 2021, 121, 659-675.	3.4	16
94	The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin. PLoS ONE, 2015, 10, e0132629.	2.5	15
95	Is increased platelet turnover responsible for low responsiveness to different thienopyridienes? A case report of recurrent stent thromboses. Thrombosis and Haemostasis, 2011, 106, 182-184.	3.4	14
96	Benefits and shortcomings of mandatory first aid and basic life support courses for learner drivers. Resuscitation, 2011, 82, 614-617.	3.0	14
97	Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. Journal of the American Heart Association, 2017, 6, .	3.7	14
98	Effectiveness and safety of self-managed oral anticoagulant therapy compared with direct oral anticoagulants in patients with atrial fibrillation. Scientific Reports, 2018, 8, 15805.	3.3	14
99	Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis. Platelets, 2019, 30, 322-328.	2.3	14
100	Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment. Thrombosis Research, 2016, 148, 107-110.	1.7	13
101	Effect of remote ischaemic conditioning on coagulation and fibrinolysis. Thrombosis Research, 2016, 141, 129-135.	1.7	13
102	Limited public ability to recognise and understand the universal sign for automated external defibrillators. Heart, 2016, 102, 770-774.	2.9	13
103	Neutrophil gelatinase-associated lipocalin (NGAL) and cardiovascular events in patients with stable coronary artery disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2018, 78, 470-476.	1.2	13
104	Effectiveness and safety of direct oral anticoagulants in atrial fibrillation patients switched from vitamin K antagonists: A systematic review and metaâ€analysis. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 21-31.	2.5	13
105	Platelet aggregation and response to aspirin therapy in cardiac allograft vasculopathy. Journal of Heart and Lung Transplantation, 2020, 39, 371-378.	0.6	13
106	MicroRNA as Biomarkers for Platelet Function and Maturity in Patients with Cardiovascular Disease. Thrombosis and Haemostasis, 2022, 122, 181-195.	3.4	13
107	Antiplatelet effect of aspirin in patients with coronary artery disease. Danish Medical Journal, 2012, 59, B4506.	0.5	13
108	Clinical outcomes following real-world computed tomography angiography-derived fractional flow reserve testing in chronic coronary syndrome patients with calcification. European Heart Journal Cardiovascular Imaging, 2021, 22, 1182-1189.	1.2	12

#	Article	IF	CITATIONS
109	Contemporary Clinical Use of Aspirin: Mechanisms of Action, Current Concepts, Unresolved Questions, and Future Perspectives. Seminars in Thrombosis and Hemostasis, 2021, 47, 800-814.	2.7	12
110	Rationale and design of the worldwide prospective multicenter registry on radiation dose estimates of cardiac CT angiography in daily practice in 2017 (PROTECTION VI). Journal of Cardiovascular Computed Tomography, 2018, 12, 81-85.	1.3	12
111	The right oral antithrombotics in acute coronary syndromes. Lancet, The, 2009, 374, 1947-1948.	13.7	11
112	Autoresuscitation: A Case and Discussion of the Lazarus Phenomenon. Case Reports in Medicine, 2015, 2015, 1-5.	0.7	11
113	Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr. American Heart Journal, 2015, 170, 465-470.	2.7	11
114	Self-Management of Anticoagulant Therapy in Mechanical Heart Valve Patients: A Matched Cohort Study. Annals of Thoracic Surgery, 2016, 101, 1494-1499.	1.3	11
115	Antiplatelet effect of aspirin during 24 h in patients with type 2 diabetes without cardiovascular disease. Thrombosis Research, 2018, 161, 1-6.	1.7	11
116	Real-world experience with reversal of dabigatran by idarucizumab. Thrombosis Research, 2021, 197, 179-184.	1.7	11
117	Combining aspirin and proton pump inhibitors: for whom the warning bell tolls?. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1051-1055.	3.3	10
118	Shear-induced platelet aggregation in aspirin-treated patients: Initial experience with the novel PlaCor PRT® device. Thrombosis Research, 2012, 130, 753-758.	1.7	10
119	Can we improve the efficacy of low-dose aspirin?. Thrombosis and Haemostasis, 2014, 112, 1077-1078.	3.4	10
120	Switching, Adverse Effects and Use of Overâ€theâ€Counter Analgesics among Users of Oral Anticoagulants: A Pharmacyâ€based Survey. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 37-43.	2.5	10
121	Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention. Expert Opinion on Pharmacotherapy, 2017, 18, 875-883.	1.8	10
122	Platelet Function and Turnover in Essential Thrombocythemia: A Systematic Review. Seminars in Thrombosis and Hemostasis, 2021, 47, 090-101.	2.7	10
123	Self-managed oral anticoagulant therapy: a call for implementation. Expert Review of Cardiovascular Therapy, 2016, 14, 255-257.	1.5	9
124	Recurrent Cardiovascular Events Despite Antiplatelet Therapy in a Patient with Polycythemia Vera and Accelerated Platelet Turnover. American Journal of Case Reports, 2017, 18, 945-948.	0.8	9
125	Cohort selection in registerâ€based studies of direct oral anticoagulant users with atrial fibrillation: An inevitable tradeâ€off between selection bias and misclassification. Basic and Clinical Pharmacology and Toxicology, 2020, 127, 3-5.	2.5	9
126	A 19-Year-Old Man with a History of Recreational Inhalation of Nitrous Oxide with Severe Peripheral Neuropathy and Central Pulmonary Embolism. American Journal of Case Reports, 2021, 22, e931936.	0.8	9

#	Article	IF	CITATIONS
127	Coronary Flow Velocity Reserve and Myocardial Deformation Predict Long-Term Outcomes in Heart Transplant Recipients. Journal of the American Society of Echocardiography, 2021, 34, 1294-1302.	2.8	9
128	Monitoring aspirin therapy with the Platelet Function Analyzerâ€100. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 786-792.	1.2	8
129	The Risk of Thromboembolism in Users of Antidepressants and Antipsychotics. Advances in Experimental Medicine and Biology, 2016, 906, 351-361.	1.6	8
130	The ABO locus is associated with increased platelet aggregation in patients with stable coronary artery disease. International Journal of Cardiology, 2019, 286, 152-158.	1.7	8
131	Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction. Contemporary Clinical Trials Communications, 2020, 19, 100629.	1.1	8
132	Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants. Cancer Medicine, 2021, 10, 4405-4414.	2.8	8
133	Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998â $\in$ 2018. Scientific Reports, 2021, 11, 13603.	3.3	8
134	Direct mail improves knowledge of basic life support guidelines in general practice: a randomised study. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2012, 20, 72.	2.6	7
135	Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs. Advances in Experimental Medicine and Biology, 2016, 906, 325-350.	1.6	7
136	The ABO Locus is Associated with Increased Fibrin Network Formation in Patients with Stable Coronary Artery Disease. Thrombosis and Haemostasis, 2020, 120, 1248-1256.	3.4	7
137	Association of whole blood microRNA expression with platelet function and turnover in patients with coronary artery disease. Thrombosis Research, 2022, 211, 98-105.	1.7	7
138	Aspirin resistance: myth or major problem?. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 257-259.	1.2	6
139	Fatal stroke following treatment with apixaban in a patient with atrial fibrillation and left atrial appendage thrombus. International Journal of Cardiology, 2016, 214, 131-132.	1.7	6
140	Pre-admission use of platelet inhibitors and short-term stroke mortality: a population-based cohort study. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 158-165.	3.0	6
141	Micro―and macrovascular cardiac allograft vasculopathy in relation to 91 cardiovascular biomarkers in heart transplant recipientsâ€"An exploratory study. Clinical Transplantation, 2021, 35, e14133.	1.6	6
142	Oral antiâ€coagulant treatment patterns in atrial fibrillation patients diagnosed with cancer: A Danish nationwide cohort study. British Journal of Haematology, 2022, 197, 223-231.	2.5	6
143	Charging the defibrillator before rhythm check reduces hands-off time during CPR: A randomised simulation study. Resuscitation, 2012, 83, e210-e211.	3.0	5
144	Platelet count, platelet turnover and fibrin clot structure in patients with coronary artery disease. Thrombosis Research, 2014, 133, 1161-1163.	1.7	5

#	Article	IF	CITATIONS
145	Inconsistencies in reporting of renal elimination among NOACs: the case of apixaban. Pharmacoepidemiology and Drug Safety, 2016, 25, 346-348.	1.9	5
146	Haematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 7, 373-379.	3.0	5
147	Impact of Dose Reduction Strategies on Image Quality of Coronary CTA in Real-World Clinical Practice: A Subanalysis of PROTECTION VI Registry Data. American Journal of Roentgenology, 2021, 217, 1344-1352.	2.2	5
148	Late Obstructive Transcatheter Heart Valve Thrombosis Resolved by Rivaroxaban. American Journal of Case Reports, 2017, 18, 573-575.	0.8	5
149	Angiotensin II inhibition increases cellular glucose transport during reperfusion but not ischemia in pig hearts. Scandinavian Cardiovascular Journal, 2003, 37, 205-210.	1.2	4
150	Preadmission use of selective serotonin reuptake inhibitors and shortâ€term mortality in diabetic patients hospitalized due to stroke. Journal of Internal Medicine, 2016, 280, 407-418.	6.0	4
151	Effect of remote ischaemic conditioning on platelet aggregation and platelet turnover. Journal of Thrombosis and Thrombolysis, 2018, 46, 528-533.	2.1	4
152	Lower Antiplatelet Effect of Aspirin in Essential Thrombocythemia than in Coronary Artery Disease. TH Open, 2021, 05, e230-e238.	1.4	4
153	Coronary CT angiography derived FFR in patients with left main disease. International Journal of Cardiovascular Imaging, 2021, 37, 3299-3308.	1.5	4
154	Life-Threatening Contraceptive-Related Pulmonary Embolism in a 14-Year-Old Girl with Hereditary Thrombophilia. American Journal of Case Reports, 2015, 16, 667-669.	0.8	4
155	International Sign for Automated External Defibrillator. Annals of Emergency Medicine, 2009, 54, 855-856.	0.6	3
156	P2Y12 inhibitors in acute coronary syndromes: How do we choose the best drug for our patients?. Thrombosis and Haemostasis, 2012, 108, 203-205.	3.4	3
157	Prolonged outpatient vitamin K antagonist use and risk of venous thromboembolism in patients undergoing total hip or knee replacement. Journal of Thrombosis and Haemostasis, 2013, 11, 642-650.	3.8	3
158	Left atrial papillary fibroelastoma as an unusual cause of myocardial infarction. BMJ Case Reports, 2014, 2014, bcr2014206665-bcr2014206665.	0.5	3
159	Successful implementation of the European Resuscitation Council basic life support course as mandatory peer-led training for medical students. European Journal of Emergency Medicine, 2014, 21, 142-144.	1.1	3
160	The SH2B3 and KCNK5 loci may be implicated in regulation of platelet count, volume, and maturity. Thrombosis Research, 2017, 158, 86-92.	1.7	3
161	Complex antithrombotic combinations: how to find the perfect blend?. Heart, 2020, 106, 557-558.	2.9	3
162	Prognostic value of myocardial perfusion imaging after first-line coronary computed tomography angiography: A multi-center cohort study. Journal of Cardiovascular Computed Tomography, 2022, 16, 34-40.	1.3	3

#	Article	IF	Citations
163	Efficacy and Safety of Oral Anticoagulants in Patients with Systolic Heart Failure in Sinus Rhythm: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Cohort Studies. TH Open, 2020, 04, e383-e392.	1.4	3
164	Direct Oral Anticoagulants After Percutaneous Patent Foramen Ovale (PFO) Closure: A Call for Caution. American Journal of Case Reports, 2020, 21, e922467.	0.8	3
165	Cytoreductive treatment and association with platelet function and maturity in patients with essential thrombocythaemia. British Journal of Haematology, 2022, 198, 693-702.	2.5	3
166	Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study. International Journal of Cardiology, 2022, 365, 34-40.	1.7	3
167	Visual-aided directions are superior to verbal instruction only in obtaining hand position for cardiopulmonary resuscitation. American Journal of Emergency Medicine, 2011, 29, 1178-1181.	1.6	2
168	Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease: reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2011, 9, 889-890.	3.8	2
169	Intraosseous Catheter Placement in Children. New England Journal of Medicine, 2011, 364, 2171-2171.	27.0	2
170	Differential vascular effects of aspirin in people with Type 2 diabetes without cardiovascular disease and matched controls without diabetes. Diabetic Medicine, 2019, 36, 1141-1148.	2.3	2
171	Antiplatelet effects of citalopram in patients with ischaemic stroke: A randomized, placebo-controlled, double-blind study. Scientific Reports, 2019, 9, 20048.	3.3	2
172	Benefits and Harm of Treatment with P2Y12 Inhibitors beyond 12 Months in Patients with Coronary Artery Disease. Seminars in Thrombosis and Hemostasis, 2020, 46, 446-456.	2.7	2
173	Initiation of and persistence with P2Y12 inhibitors in patients with myocardial infarction according to revascularization strategy: a nationwide study. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 774-786.	1.0	2
174	Effectiveness and safety of oral anticoagulation treatment beyond 1Âyear after venous thromboembolism in patients at intermediate recurrence risk. Basic and Clinical Pharmacology and Toxicology, 2021, 129, 210-220.	2.5	2
175	Apixaban or rivaroxaban in the treatment of acute venous thromboembolism?. Annals of Translational Medicine, 2019, 7, S206-S206.	1.7	2
176	Flow Cytometric Assessment of Changes in Platelet Reactivity after Acute Coronary Syndrome: A Systematic Review. Seminars in Thrombosis and Hemostasis, 2022, , .	2.7	2
177	Cardiac Arrest Caused by Multiple Recurrent Pulmonary Embolism. Case Reports in Medicine, 2011, 2011, 1-4.	0.7	1
178	Thrombopoietin and platelet aggregation in patients with stable coronary artery disease. Platelets, 2017, 28, 822-824.	2.3	1
179	Cardiovascular events after discontinuation of low-dose aspirin. Journal of Thoracic Disease, 2018, 10, 75-78.	1.4	1
180	Large Solid Right Atrial Thrombus Treated by AngioVac Catheter-Based Suction Thrombectomy. Case Reports in Cardiology, 2018, 2018, 1-3.	0.2	1

#	Article	IF	CITATIONS
181	Computed Tomography–Derived Fractional Flow Reserve in Patients With Chronic Coronary Syndrome: A Real-World Cohort Study. Journal of Computer Assisted Tomography, 2021, 45, 408-414.	0.9	1
182	Statistical and machine learning methods for analysis of multiplex protein data from a novel proximity extension assay in patients with ST-elevation myocardial infarction. Scientific Reports, 2021, 11, 13787.	3.3	1
183	Different perceptions of thorax anatomy and hand placement for chest compressions among healthcare professionals and laypersons: Implications for cardiopulmonary resuscitation. Resuscitation Plus, 2021, 7, 100138.	1.7	1
184	Hematuria in anticoagulated patients with atrial fibrillation and urologic cancer. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12629.	2.3	1
185	Warfarin monitoring and interference by lupus anticoagulant in patients with antiphospholipid syndrome. Thrombosis Research, 2022, 211, 127-132.	1.7	1
186	Aspirin and coronary artery disease. Heart, 2010, 96, 1684-1684.	2.9	0
187	Editorial: Paving the Way for Improved Antiplatelet Therapy. Current Pharmaceutical Design, 2012, 18, 5195-5196.	1.9	0
188	Reply to Letter: Basic Life Support-becoming more complex. Resuscitation, 2012, 83, e25-e26.	3.0	0
189	Letter by Grove and Kristensen Regarding Article, "Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With ST-segment–elevation Myocardial Infarction― Circulation: Cardiovascular Interventions, 2013, 6, e28.	3.9	0
190	Huge right atrial thrombus after discontinuation of anticoagulant therapy in atrial fibrillation. BMJ Case Reports, 2014, 2014, bcr2014204999-bcr2014204999.	0.5	0
191	Response: Is heart failure a debatable endâ€point for bisphosphonate treatment in an older osteoporotic population?. Journal of Internal Medicine, 2014, 275, 198-198.	6.0	0
192	Coronary stents and non-cardiac surgery: to bridge or not to bridge?. Thrombosis and Haemostasis, 2015, 114, 211-213.	3.4	0
193	Large atrial mass in a patient with Crohn's disease: organised thrombus mimicking a myxoma. BMJ Case Reports, 2017, 2017, bcr-2017-222044.	0.5	0
194	P2894Effectiveness and safety of self-managed oral anticoagulant therapy compared with direct oral anticoagulants in patients with atrial fibrillation: a propensity-weighted cohort study. European Heart Journal, 2018, 39, .	2.2	0
195	P4237Gastrointestinal bleeding is associated with gastrointestinal cancer in patients with atrial fibrillation treated with anticoagulants - a nationwide study. European Heart Journal, 2018, 39, .	2.2	0
196	P804The ABO gene locus is associated with increased platelet aggregation in stable coronary artery disease patients. European Heart Journal, 2018, 39, .	2.2	0
197	3288CT-derived fractional flow reserve in patients with stable angina pectoris: A real world follow-up study. European Heart Journal, 2018, 39, .	2.2	0
198	P3189Aspirin for prevention of cardiovascular events: an analysis of 27,451 patients from the Western Denmark Cardiac Computed Tomography Registry. European Heart Journal, 2018, 39, .	2.2	0

#	Article	IF	CITATIONS
199	Electrical cardioversion of atrial fibrillation and atrial flutter: manoeuvres and tips to increase its effectiveness—Authors'Âreply. Europace, 2020, 22, 1602-1602.	1.7	O
200	Comorbidity and risk of venous thromboembolism after hospitalization for firstâ€time myocardial infarction: A populationâ€based cohort study. Journal of Thrombosis and Haemostasis, 2020, 18, 1974-1985.	3.8	0
201	Impact of centrifugation time and pneumatic tube transport on plasma concentrations of direct oral anticoagulants. International Journal of Laboratory Hematology, 2021, , .	1.3	0
202	Increased Inflammatory Markers in Patients with Reduced Antiplatelet Effect of Aspirin Blood, 2012, 120, 2252-2252.	1.4	0
203	P4792Dabigatran versus vitamin K antagonists in patients with atrial fibrillation and valvular heart disease. European Heart Journal, 2019, 40, .	2.2	0
204	Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs. Advances in Experimental Medicine and Biology, 2015, , .	1.6	0
205	The Risk of Thromboembolism in Users of Antidepressants and Antipsychotics. Advances in Experimental Medicine and Biology, 2016, , .	1.6	0
206	Coronary Atherosclerosis and Aortic Valve Disease as Long-Term Sequelae of Radiation Therapy in Childhood. Case Reports in Cardiology, 2021, 2021, 1-2.	0.2	0
207	Platelet function testing in atherothrombotic disease: steps forward in managing resistance to antiplatelet therapy. Kardiologia Polska, 2008, 66, 478-9.	0.6	0